摘要
特发性膜性肾病(IMN)多以大量蛋白尿、低蛋白血症、浮肿、高脂血症等肾病综合征表现起病,是我国原发性肾小球肾炎中常见类型。个体预后差异较大。免疫抑制剂是治疗IMN中主要药物之一。糖皮质激素、烷化剂(环磷酰胺/苯丁酸氮芥)、钙调磷酸酶抑制剂(环孢素/他克莫司)、雷公藤等免疫抑制剂在治疗IMN具有重要地位。最近研究显示新型免疫抑制剂如利妥昔单抗、吗替麦考酚酯、来氟米特、促肾上腺皮质激素等在治疗IMN中也具有一定前景。
Idiopathic membranous nephropathy (IMN)is one of the common types of primary glomerulonephritis in our country,and mainly manifests symptoms and signs of nephrotic syndrome, including massive proteinuria,hypoproteinemia,edema,and hyperlipidemia,etc.Individual prognosis has great differences.Immunosuppressive agent is one of the main therapeutic medicines for IMN,among which the glucocorticoids, alkylating agents (cyclophosphamide /chlorambucil ), calcineurin inhibitors (cyclosporine /tacrolimus),and Tripterygium wilfordii,etc,play important roles in the treatment of IMN. Recent studies showed that new immunosuppressive agents,such as rituximab,mycophenolate mofetil, leflunomide,and adrenocorticotropic hormone also had certain prospects in the treatment of IMN.
出处
《中华肾病研究电子杂志》
2015年第6期1-4,共4页
Chinese Journal of Kidney Disease Investigation（Electronic Edition）
关键词
特发性膜性肾病
免疫抑制剂
治疗
Idiopathic membranous nephropathy
Immunosuppressive agent
Treatment
